A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Aromatase Inhibitor|DRUG: Bevacizumab|DRUG: Epirubicine|DRUG: 5-Fluorouracil (5FU)|DRUG: Cyclophosphamide|DRUG: Paclitaxel|DRUG: Docetaxel
Sponsor: Hoffmann-La Roche
Collaborators: Norwegian Radium Hospital